IN2014MN01594A - - Google Patents
Info
- Publication number
- IN2014MN01594A IN2014MN01594A IN1594MUN2014A IN2014MN01594A IN 2014MN01594 A IN2014MN01594 A IN 2014MN01594A IN 1594MUN2014 A IN1594MUN2014 A IN 1594MUN2014A IN 2014MN01594 A IN2014MN01594 A IN 2014MN01594A
- Authority
- IN
- India
- Prior art keywords
- agent
- strain
- mtb
- allergic
- asthma
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to an agent for the treatment or prevention of an allergic condition such as asthma in a mammal. The agent comprises fragments of a complex (MTB C) strain. These particular fragments may be from a virulent MTB C strain and/or in the form of a liposome composition. The agent may include further components such as a liposome forming agent and/or particular proteins from the MTB C strain. A particular allergic response that may be treated by the agent of the invention is allergic asthma. A pharmaceutical composition comprising the agent is also provided. Administration of the agent described herein significantly attenuates airway hyperresponsiveness eosinophilia and lymphocytosis in the airways of sensitized animals. The effectiveness of the agent exceeds on all the evaluated parameters the commercial vaccine BCG Danish 1331 Strain.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2012/000353 WO2013104943A1 (en) | 2012-01-12 | 2012-01-12 | Mtb-c vaccine against asthma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN01594A true IN2014MN01594A (en) | 2015-05-08 |
Family
ID=45852617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1594MUN2014 IN2014MN01594A (en) | 2012-01-12 | 2012-01-12 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9682042B2 (en) |
| EP (1) | EP2802345B1 (en) |
| CN (1) | CN104411326B (en) |
| AU (1) | AU2012365465B2 (en) |
| BR (1) | BR112014017217B1 (en) |
| CA (1) | CA2861074C (en) |
| DK (1) | DK2802345T3 (en) |
| ES (1) | ES2670493T3 (en) |
| IN (1) | IN2014MN01594A (en) |
| NO (1) | NO2802345T3 (en) |
| PL (1) | PL2802345T3 (en) |
| PT (1) | PT2802345T (en) |
| RU (1) | RU2602771C2 (en) |
| WO (1) | WO2013104943A1 (en) |
| ZA (1) | ZA201405107B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103720657B (en) * | 2013-11-19 | 2017-01-04 | 广东丸美生物技术股份有限公司 | The preparation method of a kind of deformable liposome, and the transmutability liposome of preparation |
| RU2652752C1 (en) * | 2017-06-15 | 2018-04-28 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фундаментальной и клинической иммунологии" | Method of treatment of bronchial asthma |
| EP3797791A1 (en) * | 2019-09-26 | 2021-03-31 | Universidad De Zaragoza | Therapeutic efficacy by pulmonary delivery of live attenuated mycobacteria |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP9900378A3 (en) | 1995-02-22 | 1999-11-29 | Adcock Ingram Ltd | A method for the isolation and purification of lipid cell-wall components |
| GB9813100D0 (en) | 1998-06-18 | 1998-08-19 | Secr Defence | Method of forming liposomes |
| US20030022854A1 (en) | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
| BR0103887C1 (en) | 2001-07-17 | 2005-11-08 | Univ Minas Gerais | Immunogenic compositions containing biodegradable microspheres encapsulating antigens, gene vectors and adjuvants |
| ES2231037B1 (en) | 2003-10-31 | 2005-12-16 | Archivel Technologies, Sl | USEFUL IMMUNOTHERAPIC AGENT FOR THE COMBINED TREATMENT OF TUBERCULOSIS IN ASSOCIATION WITH OTHER PHARMACOS. |
| EP1761662A4 (en) | 2004-07-01 | 2010-02-03 | Univ California | HIGH FLOW PROTEOMICS |
| PT2426141E (en) | 2005-04-29 | 2014-11-25 | Glaxosmithkline Biolog Sa | Method for preventing or treating m tuberculosis infection |
| WO2007022152A2 (en) | 2005-08-15 | 2007-02-22 | The Research Foundation Of State University Of New York | Lipid nano particulates containing antigens as cancer vaccines |
| US9393215B2 (en) | 2005-12-02 | 2016-07-19 | Novartis Ag | Nanoparticles for use in immunogenic compositions |
| TW200806317A (en) | 2006-03-20 | 2008-02-01 | Wyeth Corp | Methods for reducing protein aggregation |
| US20090081284A1 (en) * | 2006-04-20 | 2009-03-26 | Tokai University Educational System | Therapeutic agent for allergy containing liposome having oligosaccharide on its surface |
| HUE031951T2 (en) | 2006-10-10 | 2017-08-28 | Jina Pharmaceuticals Inc | Aqueous systems for the preparation of lipid-based pharmaceutical compounds; compositions, methods, and uses thereof |
| ES2307402B1 (en) | 2006-10-30 | 2009-09-30 | Archivel Farma, S.L. | PROFILACTIC VACCINE AGAINST TUBERCULOSIS. |
| CN101969976A (en) | 2008-01-11 | 2011-02-09 | 美国政府健康与人类服务部秘书处 | Peptide Vaccines and Vaccination Strategies Against Mycobacteria |
| ES2335177B1 (en) * | 2008-09-19 | 2011-02-28 | Archivel Farma, S.L. | PROPER IMMUNOTHERAPEUTIC AGENT FOR THE PRIMARY PROFILAXIS OF TUBERCULOSIS. |
| EP2421557B1 (en) | 2009-04-24 | 2018-12-05 | Statens Serum Institut | A tuberculosis tb vaccine to prevent reactivation |
| SG190937A1 (en) | 2010-12-14 | 2013-07-31 | Glaxosmithkline Biolog Sa | Mycobacterium antigenic composition |
-
2012
- 2012-01-12 IN IN1594MUN2014 patent/IN2014MN01594A/en unknown
- 2012-01-12 CN CN201280071390.0A patent/CN104411326B/en not_active Expired - Fee Related
- 2012-01-12 BR BR112014017217-0A patent/BR112014017217B1/en not_active IP Right Cessation
- 2012-01-12 PL PL12709369T patent/PL2802345T3/en unknown
- 2012-01-12 CA CA2861074A patent/CA2861074C/en active Active
- 2012-01-12 DK DK12709369.8T patent/DK2802345T3/en active
- 2012-01-12 NO NO12709369A patent/NO2802345T3/no unknown
- 2012-01-12 WO PCT/IB2012/000353 patent/WO2013104943A1/en not_active Ceased
- 2012-01-12 US US14/371,613 patent/US9682042B2/en not_active Expired - Fee Related
- 2012-01-12 EP EP12709369.8A patent/EP2802345B1/en not_active Not-in-force
- 2012-01-12 PT PT127093698T patent/PT2802345T/en unknown
- 2012-01-12 ES ES12709369.8T patent/ES2670493T3/en active Active
- 2012-01-12 RU RU2014133042/15A patent/RU2602771C2/en active
- 2012-01-12 AU AU2012365465A patent/AU2012365465B2/en not_active Ceased
-
2014
- 2014-07-11 ZA ZA201405107A patent/ZA201405107B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2861074C (en) | 2018-11-06 |
| AU2012365465A1 (en) | 2014-08-21 |
| CA2861074A1 (en) | 2013-07-18 |
| EP2802345B1 (en) | 2018-03-07 |
| DK2802345T3 (en) | 2018-04-30 |
| ES2670493T3 (en) | 2018-05-30 |
| AU2012365465B2 (en) | 2017-05-18 |
| PL2802345T3 (en) | 2018-08-31 |
| NO2802345T3 (en) | 2018-08-04 |
| CN104411326B (en) | 2018-02-02 |
| US20150132364A1 (en) | 2015-05-14 |
| PT2802345T (en) | 2018-04-24 |
| EP2802345A1 (en) | 2014-11-19 |
| WO2013104943A1 (en) | 2013-07-18 |
| ZA201405107B (en) | 2020-11-25 |
| RU2014133042A (en) | 2016-02-27 |
| RU2602771C2 (en) | 2016-11-20 |
| BR112014017217A8 (en) | 2017-07-04 |
| BR112014017217B1 (en) | 2023-01-17 |
| US9682042B2 (en) | 2017-06-20 |
| CN104411326A (en) | 2015-03-11 |
| BR112014017217A2 (en) | 2017-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201690541A1 (en) | DRY POWDER PREPARATION CONTAINING PHOSPHODESTERASE INHIBITOR | |
| WO2014045254A3 (en) | Human betacoronavirus lineage c and identification of n-terminal dipeptidyl peptidase as its virus receptor | |
| HK1212249A1 (en) | Bioconjugates comprising modified antigens and uses thereof | |
| MX2013003817A (en) | Suppression of a hypersensitivity immune response with unrelated antigen derived from allergen source material. | |
| IN2015DN00376A (en) | ||
| MX2022004103A (en) | An inhalable rapamycin formulation for treating age-related conditions. | |
| WO2014127917A8 (en) | Combination of vaccination and inhibition of the pd-1 pathway | |
| IN2015KN00414A (en) | ||
| WO2014121298A3 (en) | Methods of populating a gastrointestinal tract | |
| WO2013059559A3 (en) | Compounds and methods for enhancing innate immune responses | |
| MX2016010373A (en) | Rapamycin for the treatment of lymphangioleiomyomatosis. | |
| WO2013098655A3 (en) | Vaccines directed against human enteroviruses | |
| MX381173B (en) | RAPAMYCIN FOR THE TREATMENT OF LYMPHANGIOLEIOMYOMATOSIS. | |
| MX2016009306A (en) | Epicutaneous immunorebalancing. | |
| WO2012015986A3 (en) | Substituted dioxopiperidinyl phthalimide derivatives | |
| WO2014016548A3 (en) | Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient | |
| MX364800B (en) | Improved long-acting tilmicosin and use thereof in the treatment of bovine respiratory disease complex (brdc) and in the dry cow period. | |
| WO2013036610A3 (en) | Compositions comprising mg53 and methods for the treatment and prevention of airway injury | |
| WO2014205199A3 (en) | Compositions and methods for potentiating immune response, enhancing immunotherapy, and increasing vaccine potency | |
| MX2015006370A (en) | Herbal supplements and methods of use thereof. | |
| WO2015054678A3 (en) | Human papilloma virus therapeutic vaccine | |
| WO2014052780A3 (en) | Compositions and methods of use of an inappetance-controlling compound | |
| SG10201807682PA (en) | Methods of Treating or Preventing Respiratory Conditions | |
| SG10201908089VA (en) | Novel dosing regimens of celgosivir for the treatment of dengue | |
| WO2014074817A3 (en) | Attenuated mannheimia haemolytica vaccines and methods of making and use |